Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
March 08 2022 - 4:35PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
creating and delivering engineered cells as medicines, today
announced that preclinical data from its hypoimmune T cell program
will be presented at the 2022 American Association for Cancer
Research (AACR) Annual Meeting taking place April 8-13, 2022 in New
Orleans, LA.
Sana’s hypoimmune platform has the potential to enable
transplants of allogeneic cells without immunosuppression,
including allogeneic CAR T cells. Hypoimmune cells were engineered
to eliminate HLA-I, HLA-II, and TCR expression to block activation
of T cells and B cells, as well as prevent graft versus host
disease, while also overexpressing CD47 to block both natural
killer cell and macrophage killing. The preclinical data
demonstrate these hypoimmunogenic CAR T cells are able to evade
both the innate and adaptive arms of the immune system while
retaining their antitumor activity.
Sana is utilizing this hypoimmune platform to develop a
portfolio of allogeneic CAR T cell therapies for patients with
cancer, starting with CD19-expressing B cell malignancies such as
non-Hodgkin’s lymphoma. Sana expects to file investigational new
drug applications for multiple product candidates that utilize this
platform, starting with SC291 (CD19) in 2022 and SC276 (CD19/CD22)
as early as 2023.
Poster details:
Title: |
Engineered
hypoimmune allogeneic CAR T cells as potential off-the-shelf CAR T
cell immunotherapies |
Session Category: |
Immunology |
Session Title: |
Preclinical Immunotherapy |
Abstract Number: |
5598 |
Full abstracts are available for viewing in the AACR Online
Itinerary Planner located here,
https://www.abstractsonline.com/pp8/#!/10517. The full e-poster
will be available Friday, April 8, 2022 at 1:00 p.m. ET and remain
available for viewing through Wednesday, July 13, 2022.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are more than 350
people working together to create an enduring company that changes
how the world treats disease. Sana has operations in Seattle,
Cambridge, and South San Francisco. For more information about Sana
Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision, progress, and
business plans; expectations for its development programs, product
candidates and technology platforms, including its pre-clinical,
clinical and regulatory development plans and timing expectations;
the potential uses and advantages of hypoimmune CAR T cells;
expectations for the publication of data, including in medical or
scientific journals; and expectations for and the content of the
Company’s presentations at the 2022 American Association for Cancer
Research Annual Meeting. All statements other than statements of
historical facts contained in this press release, including, among
others, statements regarding the Company’s strategy, expectations,
cash runway and future financial condition, future operations, and
prospects, are forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. The Company has based these forward-looking statements
largely on its current expectations, estimates, forecasts and
projections about future events and financial trends that it
believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. These statements are subject to risks and uncertainties
that could cause the actual results to vary materially, including,
among others, the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of the Company’s current and future research and development
programs, preclinical and clinical trials, as well as the economic,
market and social disruptions due to the ongoing COVID-19 public
health crisis. For a detailed discussion of the risk factors that
could affect the Company’s actual results, please refer to the risk
factors identified in the Company’s SEC reports, including but not
limited to its Annual Report on Form 10-K dated March 24, 2021 and
Quarterly Report on Form 10-Q dated November 8, 2021. Except as
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements for any reason.
All product and company names herein may be trademarks of their
registered owners.
Investor Relations & Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jul 2023 to Jul 2024